UPDATE 1-FDA clears use of Lilly's COVID-19 antibody therapy for kids [Reuters]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Reuters
Dec 3 (Reuters) - The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's (LLY.N) COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness. The therapy, bamlanivimab plus etesevimab, was previously authorized for children aged 12 years and older and weighed at least 88 pounds. "Children under one year of age, who are exposed to the virus that causes COVID-19, may be at particularly high risk for severe COVID-19 and this authorization addresses the medical needs of this vulnerable population," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. The FDA authorization also allows the administration of the therapy as a preventive measure in children who are exposed to the virus. The therapy, however, is not a substitute for vaccination, Cavazzoni said. Our Standards: The Thomson Reuters Trust Principles.
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin Disorder [Yahoo! Finance]Yahoo! Finance
- DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity Prevention and Management [Yahoo! Finance]Yahoo! Finance
- Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33% [Yahoo! Finance]Yahoo! Finance
- Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial [BNN Bloomberg (Canada)]BNN Bloomberg
- Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 3/28/24 - Form PX14A6G
- 3/28/24 - Form PX14A6G
- 3/22/24 - Form DEFA14A
- LLY's page on the SEC website